Consistent with this, we have observed that cell lines derived from MYCN transgenic mice are less sensitive to MDM2-p53 antagonists than human neuroblastoma cell lines (Chen et al, manuscript in preparation). The gene discussed is MYCN; the disease is neuroblastoma.